Cadila gets US drug regulator’s warning over quality issues

The company says it will action but stock market not convinced

GN Bureau | December 31, 2015



Cadila Healthcare Ltd said it received a warning from US health regulators for violating manufacturing standards at two production sites in India. The letter from the US Food and Drug Administration cites issues at Cadila's plants in Moraiya drug production site and another in Ahmedabad city where it makes drug ingredients.

Strangely, the company says that there are no products in the US market which use API of Zyfine facility.

On Thursday, Cadila said in a statement that it was "committed to resolve all the issues and revamp our quality systems and processes as the top most priority."

“The company has received a warning letter issued by the US FDA relating to its Moraiya formulation facility and Ahmedabad API facility (Zyfine),” Cadila Healthcare said in a regulatory filing.

Cadila said none of its products being sold in the United States used any raw materials made at the Ahmedabad plant.

"The company said it will respond to US FDA to address the observations within the statutory time permitted in the letter. The company is working hard to ensure that the commitments made to the US FDA are fully completed. The company will continue to take all necessary steps to ensure that the US FDA is fully satisfied with our remediation of the above facilities," it added.

Despite these clarifications, its shares fell by 17%. This is its biggest single-day percentage fall.

Cadila has already gained site transfer approvals for 4 of its existing products. Also, its new SEZ formulations facility (oral Oncology, oral solids) received the Establishment Inspection Report (EIR) from the USFDA.

The warning for Moraiya comes more than a year after the FDA inspected the plant in 2014, and issued a report highlighting a series of problems. Cadila said in October its work to fix the issues was complete.

Comments

 

Other News

By 2022, 37% of workforce would be employed in new job roles: Report

 In the organized manufacturing and service sector, employment is expected to increase from the current 38 million to 46-48 million by 2022, a new study has found.  All the new forms of employment are expected to add a further 20% - 25% to the workforce of the current defined “or

Govt withdraws December 31 deadline to link Aadhaar with bank accounts

A day before a Supreme Court bench takes up petitions opposing mandatory Aadhaar linkage with several government services, the government has withdrawn its December 31 deadline to link Aadhaar with bank ac

State ownership has been blatantly unsatisfactory: Oxford professor

A wide swathe of economic activities was nationalised in India after independence, and especially during Indira Gandhi’s prime ministership, for predominantly political reasons. But state ownership was also justified as a way to correct market failures, increase investible surpluses, and pursue wider

Scientists must use common man’s language: Mashelkar

Calling for improved communication in the field of science and technology, eminent scientist and chairman, National Innovation Foundation, Dr Raghunath Mashelkar has said that it is important to advance knowledge and people need to know how that knowledge is for their own good. “Public awaren

Did the Rajasthan health department do the right thing by sending data on Muslim staff to centre?

Did the Rajasthan health department do the right thing by sending data on Muslim staff to centre?

80 percent abortion in India through medicines: Lancet

 Three in four abortions in India are through drugs from chemists and informal vendors rather than from health facilities, said a report in The Lancet. An estimated 15.6 million abortions were performed in the country in 2015, reports The Lancet in its latest released paper on ‘Inciden



Video

Current Issue

Opinion

Facebook    Twitter    Google Plus    Linkedin    Subscribe Newsletter

Twitter